Literature DB >> 26200277

Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers.

Dong Xie1, Randolph Marks, Mingrui Zhang, Gening Jiang, Aminah Jatoi, Yolanda I Garces, Aaron Mansfield, Julian Molina, Ping Yang.   

Abstract

BACKGROUND: We sought to build prognostic nomograms and identify novel prognostic factors in small-cell lung cancer (SCLC) incorporating both clinical data and peripheral blood markers.
METHODS: We analyzed 938 patients with SCLC (555 extensive stage SCLC [ES-SCLC] and 383 limited stage SCLC [LS-SCLC]) diagnosed between 1997 and 2012 from a single institution. We investigated the prognostic value of pretreatment neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, red cell distribution width, hemoglobin, and other clinicopathological factors. Cox proportional hazards models determined the effects of multiple factors on overall survival (OS). Two nomograms were developed to predict median survival and 6- and 12-month OS for ES-SCLC, and 1- and 2-year OS for LS-SCLC.
RESULTS: In ES-SCLC, the multivariate Cox model identified neutrophil to lymphocyte ratio and red cell distribution width as significant prognostic factors for OS independent of age, Eastern Cooperative Oncology Group performance score, chest radiation, chemotherapy, liver metastases, and numbers of metastatic sites. In LS-SCLC, significant prognostic variables included platelet to lymphocyte ratio, age, smoking cessation, chest radiation, chemotherapy, surgery, and prophylactic cranial irradiation. The two nomograms show good accuracy in predicting OS, with a concordance index of 0.73 in both ES- and LS-SCLC.
CONCLUSION: The two nomograms incorporating hematological markers could more accurately predict individualized survival probability of SCLC than the existing models.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26200277     DOI: 10.1097/JTO.0000000000000585

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  61 in total

Review 1.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

2.  Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection.

Authors:  Zhangchi Pan; Lu Zhang; Chen Liu; Xiaobing Huang; Songfei Shen; Xiaoyan Lin; Chunmei Shi
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

Review 3.  Red cell distribution width and cancer.

Authors:  Martina Montagnana; Elisa Danese
Journal:  Ann Transl Med       Date:  2016-10

Review 4.  Immune checkpoint inhibitors and small cell lung cancer: what's new?

Authors:  Sabine Schmid; Martin Früh
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

5.  Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.

Authors:  Dong Xie; Mark S Allen; Randolph Marks; Gening Jiang; Zhifu Sun; Frances Nichols; Mingrui Zhang; Chang Chen; Marie-Christine Aubry; Aminah Jatoi; Yolanda I Garces; Aaron Mansfield; Dennis Wigle; Julian Molina; Claude Deschamps; Ping Yang
Journal:  Eur J Cardiothorac Surg       Date:  2018-06-01       Impact factor: 4.191

6.  Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.

Authors:  Ryoko Suzuki; Steven H Lin; Xiong Wei; Pamela K Allen; James W Welsh; Lauren A Byers; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2018-02-02       Impact factor: 6.280

7.  A nomogram to predict overall survival of patients with early stage non-small cell lung cancer.

Authors:  Jiahui Zhang; Jingyi Fan; Rong Yin; Liguo Geng; Meng Zhu; Wei Shen; Yuzhuo Wang; Yang Cheng; Zhihua Li; Juncheng Dai; Guangfu Jin; Zhibin Hu; Hongxia Ma; Lin Xu; Hongbing Shen
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

8.  Prognostic Nomogram for Overall Survival in Small Cell Lung Cancer Patients Treated with Chemotherapy: A SEER-Based Retrospective Cohort Study.

Authors:  Min Liang; Mafeng Chen; Shantanu Singh; Shivank Singh
Journal:  Adv Ther       Date:  2021-11-03       Impact factor: 3.845

9.  A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy.

Authors:  Xun Yuan; Zhiqin Zheng; Fangfang Liu; Yuan Gao; Wenhui Zhang; Rossana Berardi; Pranshu Mohindra; Zhengfei Zhu; Jie Lin; Qian Chu
Journal:  Transl Lung Cancer Res       Date:  2021-05

10.  Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.

Authors:  Li-Ling Huang; Xing-Sheng Hu; Yan Wang; Jun-Ling Li; Hong-Yu Wang; Peng Liu; Jian-Ping Xu; Xiao-Hui He; Xue-Zhi Hao; Pei-Di Jiang; Yu-Tao Liu; Jian Luo; Sheng-Yu Zhou; Jin-Wan Wang; Jian-Liang Yang; Yan Qin; Peng Yuan; Lin Lin; Yuan-Kai Shi
Journal:  Thorac Cancer       Date:  2021-05-09       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.